Aquestive Therapeutics, Inc. AQST Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$68.91M+17.8% | -$83.78M-21.5% | -$68.98M-6.1% | -$65.04M-19.9% | -$54.24M-22.9% | ||
| $522K-4.7% | $548K-3.0% | $565K-3.4% | $585K-10.0% | $650K-9.5% | ||
| $8.36M+9.6% | $7.62M-11.9% | $8.65M+16.1% | $7.45M+4.9% | $7.11M+0.1% | ||
| $10.53M-4.2% | $11M+0.5% | $10.95M+0.7% | $10.87M+0.7% | $10.79M+0.7% | ||
| —— | —— | —— | $1.16M+316% | -$536K+26.1% | ||
| —— | —— | —— | —— | $3.4M+22.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$1.01M-123% | -$453K-303% | ||
| $39K+4,000% | -$1K+97.0% | -$33K+55.4% | -$74K— | —— | ||
| —— | —— | —— | —— | -$12.72M+1.0% | ||
| -$3.59M-134% | $10.44M+384% | $2.15M-63.3% | $5.87M+169% | $2.18M+299% | ||
| -$43.84M+16.4% | -$52.43M-3.9% | -$50.45M-1.5% | -$49.68M-1.9% | -$48.78M-36.4% | ||
| $479K-14.8% | $562K+14.2% | $492K+46.0% | $337K+27.2% | $265K+66.7% | ||
| -$479K+14.8% | -$562K-14.2% | -$492K-46.0% | -$337K-27.2% | -$265K-66.7% | ||
| —— | —— | —— | —— | $23.25K+1.1% | ||
| $1.27M+0.1% | $1.27M— | —— | —— | —— | ||
| $436K-46.2% | $810K+2.1% | $793K-14.3% | $925K+1.5% | $911K-17.3% | ||
| $86.49M-15.8% | $102.72M+0.5% | $102.21M+391% | $20.8M-7.6% | $22.51M-73.1% | ||
| —— | —— | —— | —— | —— | ||
| $6.1M0.0% | $6.1M-0.1% | $6.11M-19.9% | $7.62M0.0% | $7.62M+7.4% | ||
| $10.53M-4.2% | $11M+0.5% | $10.95M+0.7% | $10.87M+0.7% | $10.79M+0.7% | ||
| -$3.59M-134% | $10.44M+384% | $2.15M-63.3% | $5.87M+169% | $2.18M+299% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$12.72M+1.0% | ||
| —— | —— | —— | -$1.01M-123% | -$453K-303% | ||
| —— | —— | —— | —— | —— | ||
| $39K+4,000% | -$1K+97.0% | -$33K+55.4% | -$74K— | —— | ||
| —— | —— | —— | —— | $8.75K+75.0% | ||
| —— | —— | —— | —— | $30.2M+156% | ||
| —— | —— | —— | —— | $23.25K+1.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | $65K+33.3% | $48.75K+50.0% | $32.5K+100% | $16.25K— | ||
| —— | $0-100% | $62.5K-50.0% | $125K-33.3% | $187.5K-25.0% | ||
| -$44.32M+16.4% | -$52.99M-4.0% | -$50.94M-1.8% | -$50.02M-2.0% | -$49.04M-36.5% | ||
| -$44.32M+16.4% | -$52.99M-4.0% | -$50.94M-1.8% | -$50.02M-2.0% | -$49.04M-36.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Aquestive Therapeutics, Inc. generate?
- Aquestive Therapeutics, Inc. (AQST) generated -$43.8M in operating cash flow over the trailing twelve months.
- What is Aquestive Therapeutics, Inc.'s free cash flow?
- After $479.0K of capital expenditures, Aquestive Therapeutics, Inc.'s free cash flow was -$44.3M over the trailing twelve months, up 9.6% year over year.
- Where does Aquestive Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
